Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

[1]  D. Irvine,et al.  Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env , 2021, Science Translational Medicine.

[2]  M. Andrasik,et al.  Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults , 2021, The New England journal of medicine.

[3]  Bertrand Z. Yeung,et al.  T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers , 2020, Nature Medicine.

[4]  R. Fuller,et al.  Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells , 2020, Nature Communications.

[5]  Alexander Bontempo,et al.  A Systematic Approach to HIV-1 Vaccine Immunogen Selection. , 2020, AIDS research and human retroviruses.

[6]  Rachel L. Spreng,et al.  HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens , 2020, Scientific Reports.

[7]  J. Mascola,et al.  Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability , 2019, Immunity.

[8]  J. Kublin,et al.  Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa , 2019, Science Translational Medicine.

[9]  D. Montefiori,et al.  Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge , 2019, Journal of Virology.

[10]  A. McGuire.  Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design. , 2019, Current opinion in HIV and AIDS.

[11]  S. Zolla-Pazner,et al.  Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV , 2019, Current opinion in HIV and AIDS.

[12]  B. Moss,et al.  HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge , 2019, Nature Communications.

[13]  B. Pulendran,et al.  Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants , 2019, Journal of Virology.

[14]  James Theiler,et al.  HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design , 2019, Cell host & microbe.

[15]  J. Mascola,et al.  Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation , 2018, mBio.

[16]  B. Haynes,et al.  V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity , 2018, Cell reports.

[17]  D. Burton,et al.  HIV-1 vaccine design through minimizing envelope metastability , 2018, Science Advances.

[18]  J. Kublin,et al.  Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial , 2018, The lancet. HIV.

[19]  J. Mascola,et al.  Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 , 2018, Nature Medicine.

[20]  R. Wyatt,et al.  Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies , 2018, Front. Immunol..

[21]  N. Haigwood,et al.  Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges , 2018, Journal of Virology.

[22]  B. Pulendran,et al.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques , 2018, PLoS pathogens.

[23]  R. Fuller,et al.  Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model , 2017, Cell reports.

[24]  R. Wyatt,et al.  Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response , 2017, PLoS pathogens.

[25]  E. Go,et al.  Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization , 2017, Cell reports.

[26]  K. Kent,et al.  Electron-Transfer/Higher-Energy Collision Dissociation (EThcD)-Enabled Intact Glycopeptide/Glycoproteome Characterization , 2017, Journal of The American Society for Mass Spectrometry.

[27]  Allan C. deCamp,et al.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144 , 2017, PloS one.

[28]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[29]  R. Wyatt,et al.  Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein , 2017, Immunity.

[30]  D. Burton,et al.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure , 2017, Immunity.

[31]  G. Chuang,et al.  Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer , 2017, Nature Structural &Molecular Biology.

[32]  John P. Moore,et al.  Native‐like Env trimers as a platform for HIV‐1 vaccine design , 2017, Immunological reviews.

[33]  B. Pulendran,et al.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques , 2016, Journal of Virology.

[34]  B. Moss,et al.  High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques , 2016, The Journal of Immunology.

[35]  Daniel W. Kulp,et al.  Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice , 2016, Cell.

[36]  John P. Moore,et al.  Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C , 2016, PLoS pathogens.

[37]  J. Overbaugh,et al.  Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates , 2016, Journal of Virology.

[38]  Jerome H. Kim,et al.  Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization , 2016, PLoS pathogens.

[39]  D. Burton,et al.  Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability , 2016, Nature Communications.

[40]  M. Hudgens,et al.  Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques , 2016, Journal of Virology.

[41]  Karen G. Dowell,et al.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition , 2016, Nature Medicine.

[42]  John P. Moore,et al.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.

[43]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[44]  Young Do Kwon,et al.  Crystal structure , conformational fixation , and entry-related interactions of mature ligand-free HIV-1 Env , 2016 .

[45]  R. Wyatt,et al.  Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. , 2015, Cell reports.

[46]  J. Mascola,et al.  HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies , 2015, Journal of Virology.

[47]  R. Wyatt,et al.  Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties , 2015, PLoS pathogens.

[48]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[49]  Jerome H. Kim,et al.  Cryptic Determinant of α4β7 Binding in the V2 Loop of HIV-1 gp120 , 2014, PloS one.

[50]  John P. Moore,et al.  CD4-induced activation in a soluble HIV-1 Env trimer. , 2014, Structure.

[51]  Jerome H. Kim,et al.  Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines , 2014, Clinical and Vaccine Immunology.

[52]  Wayne C Koff,et al.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.

[53]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[54]  Raghavan Varadarajan,et al.  A rapid, efficient, and economical inverse polymerase chain reaction-based method for generating a site saturation mutant library. , 2014, Analytical biochemistry.

[55]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[56]  Gary J. Nabel,et al.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection , 2014, PloS one.

[57]  P. Brown,et al.  Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2–V3 interaction and modulates neutralization sensitivity , 2014, Proceedings of the National Academy of Sciences.

[58]  Raphael Gottardo,et al.  Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2013, Journal of Virology.

[59]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[60]  Baoshan Zhang,et al.  Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 , 2013, Nature Structural &Molecular Biology.

[61]  Guido Ferrari,et al.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.

[62]  Allan C. deCamp,et al.  Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial , 2013, PloS one.

[63]  Tomer Hertz,et al.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.

[64]  S. Zolla-Pazner,et al.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. , 2012, Virology.

[65]  J. Yewdell,et al.  Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice , 2012, mBio.

[66]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[67]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[68]  D. Burton,et al.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 , 2010, Proceedings of the National Academy of Sciences.

[69]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[70]  Hannah Green,et al.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  Christopher Irving,et al.  Appion: an integrated, database-driven pipeline to facilitate EM image processing. , 2009, Journal of structural biology.

[72]  David C Montefiori,et al.  Measuring HIV neutralization in a luciferase reporter gene assay. , 2009, Methods in molecular biology.

[73]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[74]  Thomas E. Wales,et al.  Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis , 2006, Journal of the American Society for Mass Spectrometry.

[75]  Anchi Cheng,et al.  Automated molecular microscopy: the new Leginon system. , 2005, Journal of structural biology.

[76]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[77]  Toshihiko Ogura,et al.  Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. , 2003, Journal of structural biology.